Sandbox:Reddy 2
Hospitalized patients
Infection | Organisms | First DOC | Alternative | ||
---|---|---|---|---|---|
Osteomyelitis | Presumed hematogenous source or contiguous without vascular insufficiency | S. aureus | Vancomycin | Vanc | If S. aureus is methicillin-susceptible then cefazolin 2 g IV q8h or nafcillin 2 g IV q4h are the antibiotics of choice.
Obtain bone biopsy to determine microbiologic cause prior to initiation of antimicrobial therapy if blood cultures are negative and patient clinically stable. |
With vascular insufficiency or diabetes mellitus (e.g. severe diabetic foot ulcer) | S. aureus
Enterobacteriaceae Anaerobes |
Vancomycin
PLUS ONE OF: Piperacillin/Tazobactam 4.5 g IV q6-8h OR Ertapenem 1 g IV daily |
For severe PCN allergy:
Vancomycin PLUS ONE OF: Ciprofloxacin400 mg IV q12h OR Levofloxacin 750 mg IV daily OR Aztreonam 2 g IV q8h ALL WITH OR WITHOUT: Metronidazole500 mg IV q8h (if patient critically ill) |
Other organisms are possible, esp. with hardware microbiologic diagnosis and ID consultation recommended
Obtain bone biopsy to determine microbiologic cause prior to initiation of antimicrobial therapy if patient clinically stable Once stable, switch to oral antibiotics based on susceptibility results. | |
Septic Arthritis | S. aureus
Streptococci spp. N. gonorrhoeae Enterobacteriaceae (rarely) |
Vancomycin
PLUS Ceftriaxone1 g IV daily |
For severe PCN allergy:
Vancomycin PLUS ONE OF: Ciprofloxacin 400 mg IV q12h OR Levofloxacin 500 mg IV daily OR Aztreonam g IV q8h if gonococcus is strongly suspected |
Gram stain recommended to guide therapy.
Narrow coverage to microbiologically confirmed pathogens. |
Brain abscess | Streptococci (anaerobic or aerobic)
Bacteroides spp Prevotella spp Enterobacteriacea |
Ceftriaxone
2 g IV q12h PLUS Metronidazole 500 mg PO/IV q8h WITH OR WITHOUT*: Vancomycin |
Aztreonam
2 g IV q8h PLUS Vancomycin PLUS Metronidazole 500 mg PO/IV q8h |
Consider expanded Gram-positive coverage if patient at risk for drug-resistant streptococci or MRSA |
Meningitis
Community-onset |
S. pneumoniae
Neisseria meningitidis Listeria (especially in immuno-compromised, elderly patients, and alcoholics) |
ceftriaxone
2 g IV q12h PLUS Vancomycin WITH OR WITHOUT* one of: TMP/SMX 15 mg/kg/day (in divided doses) OR 'Ampicillin' 2 g IV q4h |
For severe PCN allergy:
Vancomycin PLUS Aztreonam2 g IV q6h-q8h WITH OR WITHOUT*: TMP/SMX (if Listeria) 15 mg/kg/day (in divided doses) |
Therapy should be guided by Gram stain.
If bacterial meningitis suspected, dexamethasone 10 mg PO/IV q6h x 4 days given before or with initial dose of antibiotics. *Coverage for Listeria with TMP/SMX or ampicillin should be added for patients who are <2 or >50 years of age or immunocompromised. |
Meningitis
Post-neurosurgical or device associated |
S. aureus
Coagulase negative Staphylococci Gram negative rods |
Cefepime
PLUS 'Vancomycin' |
For severe PCN allergy:
Aztreonam 2 g IV q6h-q8h PLUS Vancomycin |
Native Valve | S. aureus
Streptococci spp. Enterococcus spp. Occasional gram negative rods HACEK < 5% |
Vancomycin
WITH or WITHOUT* Ceftriaxone 2 g IV daily |
For severe PCN allergy:
Vancomycin WITH or WITHOUT* CiprofloxacinID-R: VASF 400 mg IV q12h |
Narrow coverage to microbiologically confirmed pathogens
*Addition of Gram-negative coverage should be considered if the patient has a sub-acute presentation. |
Prosthetic Valve | S. aureus
S. epidermidis |
Vancomycin
PLUS Rifampin300 mg PO q8h PLUS Gentamicin 1 mg/kg/dose IV q8h for initial two weeks only Single daily dose of gentamicin is not recommended |
Rifampin has numerous clinically significant drug interactions. Medication lists should be reviewed for potential drug-drug interactions with rifampin. | |